MedTrace Logo

Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers

NCT00726960 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-08-01

No results posted yet for this study

Summary

The objective of this study is to determine whether aprepitant blocks the opiate reward system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive first line therapy for early heroin abuse.

Conditions

  • Opioid-Related Disorders
  • Heroin Dependence
  • Substance-Related Disorders

Interventions

DRUG

aprepitant

Oral, 125 mg once daily for one week

DRUG

Pseudo-placebo - buprenorphine

Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets

Sponsors & Collaborators

  • Ministry of Health and Social Affairs, Sweden

    collaborator OTHER_GOV

  • County of Stockholm

    collaborator UNKNOWN

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Markus Heilig, MD, PhD · Karolinska Universitetssjukhuset

  • Johan Kakko, MD · Karolinska Universitetssjukhuset

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-12-31
Completion
2010-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726960 on ClinicalTrials.gov